Genelux
Developed a robust drug discovery capability, building a pipeline of innovative oncolytic virus-based cancer therapies and collaborates with leading medical and academic research institutions.
Launch date
Employees
Market cap
€76.6m
Enterprise valuation
€48m (Public information from Sep 2024)
Share price
$2.37 GNLX
San Diego California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | 11.1m | <1m | <1m | - | 18.2m |
| % growth | - | - | - | (98 %) | (97 %) | - | - |
| EBITDA | (11.8m) | (14.1m) | (2.0m) | (26.1m) | - | - | - |
| % EBITDA margin | - | - | (18 %) | (15326 %) | - | - | - |
| Profit | (13.6m) | (16.4m) | (5.2m) | (28.3m) | (27.3m) | (32.9m) | (33.1m) |
| % profit margin | - | - | (47 %) | (16645 %) | (569375 %) | - | (182 %) |
| EV / revenue | - | - | - | 2201.8x | 10933.3x | - | 4.1x |
| EV / EBITDA | - | - | - | -14.4x | - | - | - |
| R&D budget | 6.2m | 6.3m | 9.1m | 12.8m | - | - | - |
| R&D % of revenue | - | - | 82 % | 7510 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $480k | Seed | |
$20.0m | Convertible | ||
* | N/A | $15.0m | IPO |
* | N/A | $33.0m | Private Placement VC |
* | N/A | $18.0m | Private Placement VC |
* | N/A | $27.5m | Post IPO Equity |
| Total Funding | €65.0m | ||
Recent News about Genelux
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.